We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Cardiac Resynchronization Therapy (CRT) Efficacy Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00822146
Recruitment Status : Completed
First Posted : January 14, 2009
Last Update Posted : September 6, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
The aim of this research study is the invasive evaluation of CR therapy efficacy in patients treated with an InSync Sentry device using an external monitoring device to obtain important cardiac parameters.

Condition or disease Intervention/treatment Phase
Heart Failure Device: CRT Phase 4

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Study Start Date : December 2008
Primary Completion Date : December 2011
Study Completion Date : March 2013
Arms and Interventions

Arm Intervention/treatment
Experimental: 1 Device: CRT

Outcome Measures

Primary Outcome Measures :
  1. classified [ Time Frame: 12 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient indicated for InSync Sentry CRT device implant
  • The patient must be willing and capable of following the study protocol
  • EF ≤ 40%
  • Systolic pulmonary artery pressure derived by echocardiography > 40
  • Patients with their device functioning in a bi-ventricular mode, with defibrillation detection and therapy enabled
  • Marked released transvenous RVCoil lead

Exclusion Criteria:

  • Patients with chronic AF
  • Patients with unipolar atrial or unipolar right ventricular leads
  • Patients needing a Lower Rate faster than 110 beats per minute
  • Patients with an implanted Medtronic Sentry in whom missing one day's fluid-measurement value is undesirable
  • Patients who cannot tolerate turning off Rate Response during the study
  • Patients with acute ischemia
  • Patients whose InSync Sentry battery is at ERI or EOL status
  • Patients with "RAMware" downloaded from other studies
  • Patients with medical conditions that would limit study participation
  • Patients who are pregnant
  • Patients enrolled in another study, which could influence the result of this study
  • Patients on the heart transplantation list or patients with transplanted hearts
  • Patients is not available for follow-up care
  • Patients has not signed a consent form
  • Patients with renal failure needing dialysis
  • Patients whose compliance can expected to be poor
  • Patients with a mechanical tricuspid valve
  • Life expectation < 12 months
  • Severe PAOD (peripheral arterial occlusive disease)
  • Underage patients, pregnant or breast feeding women and female patients not using adequate contraception are excluded from participating in the study

Since right after implantation study procedure will follow, patient has to sign the informed consent before the implantation. However the following criteria are device based and can therefore not checked at time of sign off.

Therefore lead performance will be checked right after the implant and before the study specific procedure. If exclusion criteria are fulfilled patient exit the study and no study specific procedure will be done.

  • Patients with non-intact or unstable leads, as indicated on the "Quick Look" screen of the Medtronic Model 2090 programmer by the presence of lead warnings such as the following:

    • LV pacing lead impedance is > 2500 ohms
    • LV pacing lead impedance is < 200 ohms
    • A. pacing lead impedance is > 2500 ohms
    • A. pacing lead impedance is < 200 ohms
    • SVC defib lead impedance is > 200 ohms
    • SVC defib lead impedance is < 20 ohms
    • RV pacing lead impedance is > 2500 ohms
    • RV pacing lead impedance is < 200 ohms
  • Patients with atrial pacing thresholds lower than 1.0 volts at .03 ms
  • Patients with right ventricular pacing thresholds lower than 1.0 volts at .03 ms
  • Patients with left ventricular pacing thresholds lower than 1.0 volts at .03 ms
  • Patients in whom a Lower Rate cannot be programmed to achieve consistent atrial pacing for the duration of download software installed
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00822146

Deutsches Herzzentrum Berlin
Berlin, Germany, 13353
Sponsors and Collaborators
Medtronic Bakken Research Center
More Information

Responsible Party: Medtronic Bakken Research Center
ClinicalTrials.gov Identifier: NCT00822146     History of Changes
Other Study ID Numbers: CEN_G_CA_11
First Posted: January 14, 2009    Key Record Dates
Last Update Posted: September 6, 2017
Last Verified: September 2017

Keywords provided by Medtronic Bakken Research Center:

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases